The P2X7 Receptor As a Mechanistic Biomarker for Epilepsy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Mar 29

PMID 36982485

Authors

Tobias Engel

Affiliations

Soon will be listed here.

Abstract

Epilepsy, characterized by recurrent spontaneous seizures, is a heterogeneous group of brain diseases affecting over 70 million people worldwide. Major challenges in the management of epilepsy include its diagnosis and treatment. To date, video electroencephalogram (EEG) monitoring is the gold-standard diagnostic method, with no molecular biomarker in routine clinical use. Moreover, treatment based on anti-seizure medications (ASMs) remains ineffective in 30% of patients, and, even if seizure-suppressive, lacks disease-modifying potential. Current epilepsy research is, therefore, mainly focussed on the identification of new drugs with a different mechanism of action effective in patients not responding to current ASMs. The vast heterogeneity of epilepsy syndromes, including differences in underlying pathology, comorbidities and disease progression, represents, however, a particular challenge in drug discovery. Optimal treatment most likely requires the identification of new drug targets combined with diagnostic methods to identify patients in need of a specific treatment. Purinergic signalling via extracellularly released ATP is increasingly recognized to contribute to brain hyperexcitability and, consequently, drugs targeting this signalling system have been proposed as a new therapeutic strategy for epilepsy. Among the purinergic ATP receptors, the P2X7 receptor (P2X7R) has attracted particular attention as a novel target for epilepsy treatment, with P2X7Rs contributing to unresponsiveness to ASMs and drugs targeting the P2X7R modulating acute seizure severity and suppressing seizures during epilepsy. In addition, P2X7R expression has been reported to be altered in the brain and circulation in experimental models of epilepsy and patients, making it both a potential therapeutic and diagnostic target. The present review provides an update on the newest findings regarding P2X7R-based treatments for epilepsy and discusses the potential of P2X7R as a mechanistic biomarker.

Citing Articles

P2X7R antagonism suppresses long-lasting brain hyperexcitability following traumatic brain injury in mice.

Alves M, de Diego-Garcia L, Vegliante G, Moreno O, Gil B, Ramos-Cabrer P Theranostics. 2025; 15(4):1399-1419.

PMID: 39886340 PMC: 11780721. DOI: 10.7150/thno.97254.

Brain temperature, brain metabolites, and immune system phenotypes in temporal lobe epilepsy.

Mueller C, Hong H, Sharma A, Qin H, Benveniste E, Szaflarski J Epilepsia Open. 2024; 9(6):2454-2466.

PMID: 39470707 PMC: 11633690. DOI: 10.1002/epi4.13082.

Modification of Neural Circuit Functions by Microglial P2Y6 Receptors in Health and Neurodegeneration.

Zhang Y, Tang Y, Illes P Mol Neurobiol. 2024; 62(4):4139-4148.

PMID: 39400857 PMC: 11880064. DOI: 10.1007/s12035-024-04531-8.

Moxibustion pre-treatment attenuates seizure severity during status epilepticus and counteracts the proconvulsant function of the purinergic P2X7 receptor.

Zhang H, Li J, Tang Y, Tian M, Huang S, Sun M Purinergic Signal. 2024; .

PMID: 39271580 DOI: 10.1007/s11302-024-10050-x.

The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy.

Thakku Sivakumar D, Jain K, Alfehaid N, Wang Y, Teng X, Fischer W Int J Mol Sci. 2024; 25(13).

PMID: 39000004 PMC: 11241490. DOI: 10.3390/ijms25136894.

References

Cieslak M, Wojtczak A, Komoszynski M . Role of the purinergic signaling in epilepsy. Pharmacol Rep. 2016; 69(1):130-138. DOI: 10.1016/j.pharep.2016.09.018. View

Heinrich A, Ando R, Turi G, Rozsa B, Sperlagh B . K+ depolarization evokes ATP, adenosine and glutamate release from glia in rat hippocampus: a microelectrode biosensor study. Br J Pharmacol. 2012; 167(5):1003-20. PMC: 3492983. DOI: 10.1111/j.1476-5381.2012.01932.x. View

Kaczmarek-Hajek K, Zhang J, Kopp R, Grosche A, Rissiek B, Saul A . Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody. Elife. 2018; 7. PMC: 6140716. DOI: 10.7554/eLife.36217. View

. Commission on Diagnostic Strategies: recommendations for functional neuroimaging of persons with epilepsy. Epilepsia. 2000; 41(10):1350-6. DOI: 10.1111/j.1528-1157.2000.tb04617.x. View

Venereau E, Ceriotti C, Bianchi M . DAMPs from Cell Death to New Life. Front Immunol. 2015; 6:422. PMC: 4539554. DOI: 10.3389/fimmu.2015.00422. View

Beghi E . The Epidemiology of Epilepsy. Neuroepidemiology. 2019; 54(2):185-191. DOI: 10.1159/000503831. View

Wu H, Nie Y, Xiong H, Liu S, Li G, Huang A . P2X7 Receptor Expression in Peripheral Blood Monocytes Is Correlated With Plasma C-Reactive Protein and Cytokine Levels in Patients With Type 2 Diabetes Mellitus: a Preliminary Report. Inflammation. 2015; 38(6):2076-81. DOI: 10.1007/s10753-015-0189-y. View

Loscher W . Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011; 20(5):359-68. DOI: 10.1016/j.seizure.2011.01.003. View

Sakamoto S, Miyaji T, Hiasa M, Ichikawa R, Uematsu A, Iwatsuki K . Impairment of vesicular ATP release affects glucose metabolism and increases insulin sensitivity. Sci Rep. 2014; 4:6689. PMC: 4204045. DOI: 10.1038/srep06689. View

10.

Rozmer K, Gao P, Araujo M, Khan M, Liu J, Rong W . Pilocarpine-Induced Status Epilepticus Increases the Sensitivity of P2X7 and P2Y1 Receptors to Nucleotides at Neural Progenitor Cells of the Juvenile Rodent Hippocampus. Cereb Cortex. 2016; 27(7):3568-3585. DOI: 10.1093/cercor/bhw178. View

11.

Martinez-Garcia J, Martinez-Banaclocha H, Angosto-Bazarra D, Torre-Minguela C, Baroja-Mazo A, Alarcon-Vila C . P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis. Nat Commun. 2019; 10(1):2711. PMC: 6586640. DOI: 10.1038/s41467-019-10626-x. View

12.

Garcia-Villalba J, Hurtado-Navarro L, Penin-Franch A, Molina-Lopez C, Martinez-Alarcon L, Angosto-Bazarra D . Soluble P2X7 Receptor Is Elevated in the Plasma of COVID-19 Patients and Correlates With Disease Severity. Front Immunol. 2022; 13:894470. PMC: 9161710. DOI: 10.3389/fimmu.2022.894470. View

13.

Armstrong J, Brust T, Lewis R, MacVicar B . Activation of presynaptic P2X7-like receptors depresses mossy fiber-CA3 synaptic transmission through p38 mitogen-activated protein kinase. J Neurosci. 2002; 22(14):5938-45. PMC: 6757920. DOI: 20026618. View

14.

Schmidt S, Isaak A, Junker A . Spotlight on P2X7 Receptor PET Imaging: A Bright Target or a Failing Star?. Int J Mol Sci. 2023; 24(2). PMC: 9861945. DOI: 10.3390/ijms24021374. View

15.

Barros-Barbosa A, Fonseca A, Guerra-Gomes S, Ferreirinha F, Santos A, Rangel R . Up-regulation of P2X7 receptor-mediated inhibition of GABA uptake by nerve terminals of the human epileptic neocortex. Epilepsia. 2015; 57(1):99-110. DOI: 10.1111/epi.13263. View

16.

Zhong R, Chen Q, Li M, Zhang X, Lin W . Elevated Blood C-Reactive Protein Levels in Patients With Epilepsy: A Systematic Review and Meta-Analysis. Front Neurol. 2019; 10:974. PMC: 6759543. DOI: 10.3389/fneur.2019.00974. View

17.

Vultaggio-Poma V, Falzoni S, Salvi G, Giuliani A, Di Virgilio F . Signalling by extracellular nucleotides in health and disease. Biochim Biophys Acta Mol Cell Res. 2022; 1869(5):119237. DOI: 10.1016/j.bbamcr.2022.119237. View

18.

Fischer W, Franke H, Krugel U, Muller H, Dinkel K, Lord B . Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure Models. PLoS One. 2016; 11(6):e0156468. PMC: 4900628. DOI: 10.1371/journal.pone.0156468. View

19.

Metzger M, Walser S, Dedic N, Aprile-Garcia F, Jakubcakova V, Adamczyk M . Heterozygosity for the Mood Disorder-Associated Variant Gln460Arg Alters P2X7 Receptor Function and Sleep Quality. J Neurosci. 2017; 37(48):11688-11700. PMC: 6705750. DOI: 10.1523/JNEUROSCI.3487-16.2017. View

20.

Loscher W . Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs. Neurochem Res. 2017; 42(7):1873-1888. DOI: 10.1007/s11064-017-2222-z. View